Innovative Therapies - 20/08/2020

Labor Dr. Merk is fully committed to viral therapies

Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

Review article (new edition) - 08/07/2020

Immunology – at the forefront of medical progress

Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

Article - 22/10/2019

Using CAR T cells for treating cancer

After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.

Dossier - 14/06/2016

CRISPR/Cas – genome editing is becoming increasingly popular

The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary diseases.

Baden-Württemberg is currently home to 193 biotechnology companies, most of which specialise in so-called ‘red biotechnology’ - i.e. applications in the medical and pharmaceutical sectors. The biotech sector includes not only traditional biotechnology companies, but also companies from the fields of bioinformatics, diagnostics, analytics and biotechnological production.

Dossier - 09/03/2015

Advances in the study and treatment of liver diseases

Liver diseases are often underestimated despite being quite common and potentially having serious and even life-threatening consequences, especially in chronic cases. The most common causes of liver diseases are hepatitis viruses, excessive alcohol consumption, and obesity; congenital or autoimmune liver diseases are quite rare. Thanks to advances in medical research, diseases such as hepatitis B and C can be treated effectively.

Dossier - 10/11/2014

Cell and gene therapies from bench to bedside

While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.